ROCKVILLE, Md., Dec. 14, 2004 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced that on December 8, 2004, the United States District Court for the Northern District of Illinois has entered a consent judgment against Little Rock Foot Clinic, P.A. and its owners, Marvin Cohen, R. Alex Dellinger and Calvin P. Britton, III. In that consent judgment, Little Rock Foot Clinic and its owners admitted that Cytomedix's Knighton patent, which covers the use of compositions containing platelet releasates for wound healing purposes, is valid and enforceable. The Court declared that Little Rock Foot Clinic and its owners had infringed the Knighton Patent and enjoined them, effective immediately and continuing through expiration of the Knighton patent from making, using, offering, or selling within the United States autologous cellular therapies, platelet gel products, or any other processes or products-such as the "SafeBlood Graft(tm)" formulation-that infringe the claims of the Knighton Patent. The Court's injunction is binding on Little Rock Foot Clinic and its owners, and on those acting in concert or participation with them. The Court retained jurisdiction to enforce its order of judgment.
"This and other recent successful legal judgments underscore Cytomedix's continuing commitment and strategy to aggressively pursue infringement of the company's intellectual property. We are pleased to have successfully resolved this matter and look forward to other positive developments related to our AutoloGel(tm) System," said Dr. Kshitij Mohan, chief executive officer of Cytomedix.
About Cytomedix
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates. The current product offering is AutoloGel(tm), an autologous platelet gel composed of multiple growth factors and fibrin matrix, which is used to treat chronic wounds. Cytomedix is working with healthcare providers to offer an advanced therapy at the point-of-care in multiple settings. Additional information is available at: www.cytomedix.com.
Forward Looking Statements
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, governmental regulation, acceptance by the medical community and competition. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc.